Cargando…

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage

Detalles Bibliográficos
Autores principales:	Brandenburg, Vincent, Heine, Gunnar H., Marx, Nikolaus, Stöhr, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515940/ https://www.ncbi.nlm.nih.gov/pubmed/32215701 http://dx.doi.org/10.1007/s00392-020-01630-z

Ejemplares similares

FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
por: Stöhr, Robert, et al.
Publicado: (2018)

Corrigendum: FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
por: Stöhr, Robert, et al.
Publicado: (2018)

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice
por: Hardy, S., et al.
Publicado: (2015)

FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019)

Recurrent severe hypophosphatemia following intravenous iron administration
por: Nataatmadja, Melissa Stephanie, et al.
Publicado: (2020)

Intravenous Iron Induced Severe Hypophosphatemia
por: Guo, Rong R, et al.
Publicado: (2021)

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome
por: Glaspy, John A., et al.
Publicado: (2021)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations
por: Bosman, Ariadne, et al.
Publicado: (2023)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk
por: Schaefer, Benedikt, et al.
Publicado: (2016)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
por: Kato, Hajime, et al.
Publicado: (2023)

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review
por: Glaspy, John A, et al.
Publicado: (2020)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats
por: Gravesen, Eva, et al.
Publicado: (2013)

Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2023)

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial
por: Roberts, Matthew A., et al.
Publicado: (2016)

Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials
por: Fukumoto, Seiji, et al.
Publicado: (2023)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Intravenous iron supplementation in heart failure patients induces temporary endothelial dysfunction with release of endothelial microvesicles
por: Mause, Sebastian F., et al.
Publicado: (2023)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
por: Detlie, Trond Espen, et al.
Publicado: (2021)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

Cardiac FGF23: a new player in myocardial infarction
por: Schumacher, David, et al.
Publicado: (2019)

Travelling wave kicker magnets with sharp rise and less overshoot
por: Nassibian, G
Publicado: (1979)

Travelling wave kicker magnets with sharp rise and less overshoot
por: Nassibian, G
Publicado: (1979)

Travelling wave kicker magnets with sharp rise and less overshoot
por: Nassibian, G
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_un3b8d6hoh7k37tacco88bvgum